Rentschler Biopharma’s ATMP facility in Stevenage, UK, receives MHRA approval UK site now set for clinical production of adeno-associated virus (AAV) vectors for gene therapyHighly experienced team ready to support ATMP innovators at all stagesOffering comprehensive range of...

Rentschler Biopharma joins forces with Ikarovec to accelerate novel gene therapies for treatment of ophthalmic disease Rentschler Biopharma to conduct adeno-associated virus (AAV) process development work for manufacturing scale-up at their ATMP site in Stevenage, UKIkarovec is developing novel gene therapies to treat...

Autolus Therapeutics announces handover of first clean rooms of new Stevenage, UK, manufacturing facility LONDON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces...

Rentschler Biopharma adds highly experienced executive to team and provides update on progress at Rentschler ATMP Company hires Kassim Kolia, as Vice President, Business Development to grow cell and gene therapy businessStevenage ATMP site projected to be client ready for process development in late 2022 ...